Sanofi Basic EPS 2012-2026 | SNY
Sanofi annual/quarterly basic eps history and growth rate from 2012 to 2026. Basic eps can be defined as a company's net earnings or losses attributable to common shareholders per basic share basis.
- Sanofi basic eps for the quarter ending March 31, 2026 was $0.78, a 2.12% decline year-over-year.
- Sanofi basic eps for the twelve months ending March 31, 2026 was $3.60, a 33.04% increase year-over-year.
- Sanofi annual basic eps for 2025 was $0.004B, a 50.75% increase from 2024.
- Sanofi annual basic eps for 2024 was $0.002B, a 3% increase from 2023.
- Sanofi annual basic eps for 2023 was $0.002B, a 33.83% decline from 2022.
| Sanofi Annual Basic EPS | |
|---|---|
| 2025 | $3.62 |
| 2024 | $2.40 |
| 2023 | $2.33 |
| 2022 | $3.52 |
| 2021 | $2.94 |
| 2020 | $5.61 |
| 2019 | $1.25 |
| 2018 | $2.04 |
| 2017 | $3.79 |
| 2016 | $2.03 |
| 2015 | $1.82 |
| 2014 | $2.22 |
| 2013 | $1.87 |
| 2012 | $2.42 |
| 2011 | $2.83 |
| Sanofi Quarterly Basic EPS | |
|---|---|
| 2026-03-31 | $0.78 |
| 2025-12-31 | $-0.36 |
| 2025-09-30 | $1.34 |
| 2025-06-30 | $1.84 |
| 2025-03-31 | $0.80 |
| 2024-12-31 | $0.19 |
| 2024-09-30 | $1.24 |
| 2024-06-30 | $0.48 |
| 2024-03-31 | $0.49 |
| 2023-12-31 | $-0.25 |
| 2023-09-30 | $1.10 |
| 2023-06-30 | $0.63 |
| 2023-03-31 | $0.86 |
| 2022-12-31 | $1.29 |
| 2022-09-30 | $0.84 |
| 2022-06-30 | $0.50 |
| 2022-03-31 | $0.90 |
| 2021-09-30 | $1.09 |
| 2021-06-30 | |
| 2021-03-31 | $0.75 |
| 2020-09-30 | $0.91 |
| 2020-03-31 | $0.75 |
| 2019-09-30 | $0.78 |
| 2019-03-31 | $0.52 |
| 2018-03-31 | $0.50 |
| 2017-12-31 | $0.20 |
| 2017-09-30 | $0.74 |
| 2017-06-30 | $0.45 |
| 2017-03-31 | $2.41 |
| 2016-12-31 | $0.33 |
| 2016-09-30 | $0.73 |
| 2016-06-30 | $0.51 |
| 2016-03-31 | $0.46 |
| 2015-09-30 | $0.70 |
| 2015-06-30 | $0.55 |
| 2014-06-30 | $0.41 |
| 2013-06-30 | $0.22 |
| 2012-06-30 | $0.57 |
| 2012-03-31 | $0.91 |
| 2011-12-31 | $0.71 |
| 2011-09-30 | $1.05 |
| 2011-06-30 | $0.56 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $114.048B | $49.347B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |